The FDA has recently announced a halt on compounded versions of GLP-1 receptor agonists, including semaglutide and tirzepatide, which have been pivotal in weight loss and diabetes management. These medications, widely recognized under brand names like, “Ozempic“, “Wegovy“, and “Mounjaro”, remain FDA-approved and unaffected by this decision. However, compounded versions, which are custom-made by pharmacists, […]